JULIANA AMUZU-DOE: Open Payments
NPI 1245901388 · BEAUMONT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,745 in 78 payments from 14 companies in 2025. Trend: 2023 $1,208 · 2024 $1,172 · 2025 $1,745
Food & beverage: $1,745
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $466 |
| Otsuka America Pharmaceutical, Inc. | 13 | $237 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $209 |
| E.R. Squibb & Sons, L.L.C. | 10 | $187 |
| Teva Pharmaceuticals USA, Inc. | 11 | $151 |
| Axsome Therapeutics, Inc. | 6 | $143 |
| Gilead Sciences, Inc. | 1 | $92 |
| MIMEDX Group, Inc. | 1 | $91 |
| Collegium Pharmaceutical, Inc. | 2 | $43 |
| Tris Pharma Inc | 2 | $34 |
Products named: INGREZZA, REXULTI, CAPLYTA, COBENFY, Auvelity, UZEDY, Livdelzi, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
